Literature DB >> 33877399

[The 2017 WHO classification of pituitary tumors].

Wolfgang Saeger1.   

Abstract

The 2017 WHO classification of pituitary tumors is still based on structural analyses and expression of various pituitary hormones. Three innovations have to be considered: (1) The expression of pituitary transcription factors Pit‑1, T‑Pit and SF‑1. (2) The term "atypical adenoma" was replaced by "aggressive adenoma". (3) The three tumor types of the neurohypophysis (pituicytoma, spindle cell oncocytoma, granular cell tumor) are defined by their common expression of TTF‑1. Craniophyryngiomas are identified as adamantinomatous type by focal nuclear expression of β‑catenin or as papillary type by demonstration of BRAF V600E mutation. Further primary tumors of the pituitary are extremely rare. These and also the other tumors of the sellar region can be structurally very similar to pituitary adenomas but can be-nearly without exception-differentiated by immunocytochemistry.

Entities:  

Keywords:  Adenoma; Carcinoma; Hyperplasia; Pituitary gland; Pituitary neoplasms

Year:  2021        PMID: 33877399     DOI: 10.1007/s00292-021-00932-x

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  58 in total

1.  [ACTH cell hyperplasia of the adeno- and neurohypophysis and its relation to arterial hypertension].

Authors:  W Saeger; H Schröder
Journal:  Pathologe       Date:  1985-05       Impact factor: 1.011

2.  Quantitative evaluation of the distribution of cell density. Application to human pituitary corticotroph cells.

Authors:  C Souchier; M P Guigard; P Fonlupt; J Trouillas
Journal:  Anal Quant Cytol Histol       Date:  1996-06       Impact factor: 0.302

3.  A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours.

Authors:  Evelina Sjöstedt; Jens Bollerslev; Jan Mulder; Cecilia Lindskog; Fredrik Pontén; Olivera Casar-Borota
Journal:  Acta Neuropathol       Date:  2017-08-19       Impact factor: 17.088

4.  The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph.

Authors:  S L Asa; A M Bamberger; B Cao; M Wong; K L Parker; S Ezzat
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

5.  Refractory Cushing's disease caused by multinodular ACTH-cell hyperplasia.

Authors:  P E McKeever; M C Koppelman; D Metcalf; E Quindlen; P L Kornblith; C A Strott; R Howard; B H Smith
Journal:  J Neuropathol Exp Neurol       Date:  1982-09       Impact factor: 3.685

6.  Pituitary gland in hypothyroidism. Histologic and immunocytologic study.

Authors:  B W Scheithauer; K Kovacs; R V Randall; N Ryan
Journal:  Arch Pathol Lab Med       Date:  1985-06       Impact factor: 5.534

7.  Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors.

Authors:  Wolfgang Saeger; Arend Koch
Journal:  Exp Clin Endocrinol Diabetes       Date:  2021-03-09       Impact factor: 2.949

8.  Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas.

Authors:  S L Asa; L A Puy; A M Lew; V C Sundmark; H P Elsholtz
Journal:  J Clin Endocrinol Metab       Date:  1993-11       Impact factor: 5.958

9.  The pituitary gland in untreated Addison's disease. A histologic and immunocytologic study of 18 adenohypophyses.

Authors:  B W Scheithauer; K Kovacs; R V Randall
Journal:  Arch Pathol Lab Med       Date:  1983-09       Impact factor: 5.534

Review 10.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.